For how we live.
Hovilpri (pritelivir), a helicase-primase inhibitor, was approved on 9 October for immunocompromised adults whose herpes lesions resist aciclovir. In its trial, 63% healed by day 28 against 34% on comparator therapy.
A Toronto cohort reports that an eight-day antiviral protocol prevented or cleared hepatitis C in all 116 recipients of organs from infected donors, with survival matching recipients of uninfected organs.
HRSA has finalised eligibility guidelines for its Living Organ Donation Reimbursement Program under the HOLD Act, which bars considering the recipient's income. Eligibility now turns on the donor's own income.
In the investigator-led CAVIAR trial, adding the PCSK9 inhibitor alirocumab to a statin after heart transplant more than halved LDL cholesterol but did not slow coronary plaque growth at one year.
Gene-edited islet cells implanted in a person's forearm are still functioning more than a year later. It is a single case report, and will need many more patients to mean anything.